{"id":"NCT00571727","sponsor":"Ipsen","briefTitle":"Long-Term Treatment With rhIGF-1 in GHIS","officialTitle":"A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"1991-05-20","primaryCompletion":"2011-12-15","completion":"2011-12-15","firstPosted":"2007-12-12","resultsPosted":"2023-07-06","lastUpdate":"2023-07-06"},"enrollment":92,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Insensitivity Syndrome"],"interventions":[{"type":"DRUG","name":"mecasermin","otherNames":["Increlex"]}],"arms":[{"label":"mecasermin, injections BID of rhIGF-1","type":"EXPERIMENTAL"}],"summary":"The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).","primaryOutcome":{"measure":"Annualized Height Velocity Up to 12 Years","timeFrame":"Baseline (Pre-dose) and up to 12 years","effectByArm":[{"arm":"Mecasermin","deltaMin":2.6,"sd":1.7}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17192294"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":92},"commonTop":["Hypoglycaemia","Injection site hypertrophy","Headache","Upper respiratory tract infection","Snoring"]}}